Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 21 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 12 Sep 2019
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.

Atezolizumab improves survival in extensive-stage small-cell lung cancer

Christina Lau
05 Oct 2018
Dr Stephen Liu

Atezolizumab, when added to standard-of-care chemotherapy, significantly improves survival of patients with extensive-stage small-cell lung cancer (SCLC) in the first-line setting, according to results of the IMpower133 trial reported at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC 2018).

“IMpower133 is the first study in more than 20 years to show a clinically meaningful improvement in overall survival [OS] vs current standard of care in the first-line treatment of extensive-stage SCLC. Our findings suggest that atezolizumab plus carboplatin and etoposide is a new standard of care in this setting,” said investigator Dr Stephen Liu of the Georgetown University, Washington DC, US. [Liu S, et a, WCLC 2018, abstract PL02.07; N Engl J Med 2018, doi: 10.1056/NEJMoa1809064]

In the study, 403 patients (median age, 64 years; 64.2–65.3 percent male) who had received no prior treatment for extensive-stage SCLC were randomized in a 1:1 ratio to receive four 21-day cycles of atezolizumab (1,200 mg intravenously on day 1) plus carboplatin and etoposide, or placebo plus the same chemotherapy. Following this induction phase, patients were maintained on either atezolizumab or placebo alone, according to their previous randomized assignment, until disease progression or loss of clinical benefit.

“After a median follow-up of 13.9 months, the co-primary endpoint of OS was significantly improved by 30 percent in the atezolizumab vs placebo arm,” reported Liu.

Median OS was 12.3 months in the atezolizumab arm vs 10.3 months in the placebo arm (hazard ratio [HR], 0.70; 95 percent confidence interval [CI], 0.54 to 0.91; p=0.0069). At 12 months, OS rate was 51.7 percent vs 38.2 percent.

“OS favoured atezolizumab in almost all subgroups, except in patients with treated brain metastases at baseline,” Liu noted.

Progression-free survival (PFS), another co-primary endpoint, showed a 23 percent improvement with atezolizumab vs placebo (median, 5.2 months vs 4.3 months; HR, 0.77; 95 percent CI, 0.62 to 0.96; p=0.017). “The 12-month PFS rate doubled with atezolizumab vs placebo, and was 12.6 percent vs 5.4 percent,” said Liu.

While the objective response rate did not differ significantly between the atezolizumab and placebo arms (60.2 percent vs 64.4 percent), the duration of response was slightly longer with atezolizumab vs placebo (median, 4.2 months vs 3.9 months; HR, 0.70; 95 percent CI, 0.53 to 0.92).

“The event-free rates at 6 months and 12 months were superior in the atezolizumab vs placebo arm [32.2 percent vs 17.1 percent and 14.9 percent vs 6.2 percent, respectively], as was the proportion of patients with ongoing response [14.9 percent vs 5.4 percent],” Liu noted.

In terms of safety, the investigators identified no new signals with the combination of atezolizumab plus carboplatin and etoposide. “Rates of haematologic adverse events [AEs] were similar between the two arms. The incidence and types of immune-related AEs were similar to those seen with atezolizumab monotherapy,” said Liu. “Administration of atezolizumab did not compromise the ability to deliver standard chemotherapy with carboplatin plus etoposide, as patients in both arms received the same number of doses of chemotherapy.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 11 Sep 2019

Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.

Elvira Manzano, 21 hours ago

The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.

Pearl Toh, Yesterday
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.
Stephen Padilla, 12 Sep 2019
Overweight and obesity show an inverse relationship with acne in a dose-dependent manner in young adults, according to a recent study. This suggests that the metabolically active adipose tissue plays a protective role in acne.